Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past week. The post StockWatch: Insilico Projects Profit,…
You may also like
Stem Cell Therapy Shows Promise in First Human...
Ag Genomics Begins to Bear Fruit
KKR-backed Allyntra debuts to serve medtech industry...
IHealthScreen nabs FDA nod for AI-backed dx to spot...
‘How did they get there first?’ Biotechs forced to...
Deals, deals, deals; Biohaven takes on Eli Lilly; and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.